glp-1 agonist pharmacology glp-1_analogs [TUSOM GLP-1-based therapies for type 2

Clinical outcomes such as cirrhosis progression, liver transplant, and all-cause mortality are recognized as solid endpoints for evaluating drug efficacy in MASLD

You may use the same general body area each week, but rotate the exact injection spot to prevent irritation or tissue thickening

weight loss of less than 10%, HR = 0.78

Should GEP-44 continue producing favorable results through clinical development, the company could emerge as an attractive acquisition, licensing or partnership candidate within the fast-expanding GLP ecosystem

doi: 10.1056/NEJMoa1607141 12 HernandezAFGreenJBJanmohamedSD'AgostinoRBSrGrangerCBJonesNPet al

Obesity and cancer mechanisms: Tumor microenvironment and inflammation